Overview

Oral OKT3 for the Treatment of Active Ulcerative Colitis

Status:
Completed
Trial end date:
2013-05-02
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of orally delivered short-term OKT3 in participants with active ulcerative colitis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Brigham and Women's Hospital
Treatments:
Muromonab-CD3
Omeprazole